(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/262914 A1

(51) International Patent Classification:
A61K 31/428 (2006.01) *A61P 25/00* (2006.01)

(21) International Application Number:
PCT/US2021/038789

(22) International Filing Date:
24 June 2021 (24.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/043,681 24 June 2020 (24.06.2020) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.** [US/US]; 215 Church Street, New Haven, Connecticut 06510 (US).


(72) Inventors: **CORIC, Vladimir**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **BERMAN, Robert**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **AGUIAR, Loren**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR TREATING OBSESSIVE-COMPULSIVE DISORDER



Mean Y-BOCS Total scores measured at Baseline and Weeks 4, 8 and 12 (observed case analysis) during treatment wih Troriluzole or placebo in the modified intent-to-treat population. Post-baseline p value is for change from baseline: ☆ $p \leq 0.05$

Fig. 2

(57) Abstract: Disclosed herein is a method for treating obsessive-compulsive disorder in a patient in need thereof by administering to the patient a dosage form including an effective amount of troriluzole.

[Continued on next page]

WO 2021/262914 A1

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*